Recruiting
Phase 1
Phase 2

Inulin Gel, Ipilimumab, Nivolumab

Sponsor:

University of Michigan Rogel Cancer Center

Code:

NCT06866262

Conditions

Locally Advanced Clear Cell Renal Cell Carcinoma

Locally Advanced Sarcomatoid Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

Metastatic Sarcomatoid Renal Cell Carcinoma

Stage III Renal Cell Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy

Biospecimen Collection

Computed Tomography

Inulin

Ipilimumab

Study Details

Brief summary:

This phase I/II trial tests the safety and effectiveness of inulin gel in combination with ipilimumab and nivolumab in treating patients with kidney cell cancer (renal cell carcinoma \[RCC\]) that has spread from where it first started (primary site) to other places in the body (metastatic) or has spread to nearby tissue or lymph nodes (locally advanced). Inulin is a common food additive fermentable prebiotic fiber beneficial for a healthy gut microbiome. The microbiome is the collection of all microbes, such as bacteria, fungi, viruses, and their genes, that naturally live on and inside the body. Inulin may also be used for cancer prevention and heart health, but there is less evidence to support those uses. The gut microbiome profile may improve the effectiveness of drugs called immune checkpoint inhibitors, such as ipilimumab and nivolumab. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving inulin gel in combination with ipilimumab and nivolumab may be safe and effective in treating in patients with metastatic or locally advanced RCC.

Conditions

Locally Advanced Clear Cell Renal Cell Carcinoma

Locally Advanced Sarcomatoid Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

Metastatic Sarcomatoid Renal Cell Carcinoma

Stage III Renal Cell Cancer AJCC v8

Study ID

NCT06866262

Start date

Aug 15, 2025

Status verified date

Jul, 2026

Completion date

Aug 1, 2031

Anticipated

Primary completion date

Aug 1, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient is ≥ 18 years of age on the day of signing informed consent.
  • Candidate for ipilimumab and nivolumab therapy for metastatic renal cancer per the treating physician investigator.
  • Patient has a performance status of ≤ 2 on the Zubrod performance scale.
  • Patient has a histological or cytological diagnosis of renal cancer with clear cell or sarcomatoid component.
  • Radiologic or clinical evidence of metastatic disease, or progressive locally advanced disease.
  • Absolute neutrophil count ≥ 1,500/uL.
  • Platelets ≥ 75K/μL.
  • Hemoglobin ≥ 8.5 g/dL.
  • Calculated creatinine clearance is ≥ 30 ml/min as per the Cockroft-Gault formula.
  • Direct bilirubin ≤ 1.5 x upper limit of normal (ULN) OR total bilirubin levels ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for patients with total bilirubin levels > 1.5 ULN.
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x ULN except for patients with liver metastases, AST/ALT should be ≤ 5 x ULN.
  • Patient received no prior systemic anti-cancer therapy for metastatic disease.
  • Patient has evaluable or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Bone metastases, pleural effusion or ascites will be considered evaluable disease sites.

  • Tumor mass: Must be accurately measurable in at least 1 dimension (longest diameter to be recorded) with a minimum size of:

  • 10 mm by CT scan (CT scan slice thickness no greater than 5 mm,

Or:

  • 20 mm by chest X-ray (if clearly defined and surrounded by aerated lung). With or without malignant lymph nodes: ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness must be ≤ 5 mm). The measurement should be two dimensions at axial plane. The short axis should be in perpendicular to long diameter.

  • Ability to understand and the willingness to review and sign a written informed consent.
  • Both male and female patients must agree to use adequate contraceptive measures to prevent pregnancy throughout the duration of study therapy and a minimum of -5 months after stopping therapy per package insert of ipilimumab and nivolumab.
  • Ability to ingest oral therapy.
  • Female patient of childbearing capacity has a negative pregnancy test within 7 days of starting study therapy.

Exclusion Criteria:

  • The subject has received cytotoxic therapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) or immunosuppressants (excluding steroids) within 4 weeks or antibiotics within 2 weeks of starting study therapy.
  • Patient is currently enrolled in another clinical trial testing another investigational agent, or concurrently in another approved systemic anti-cancer therapy for renal cancer.
  • Patient is on chronic systemic steroid therapy at doses > 10 mg/day prednisone equivalent or on any other immunosuppressive therapy within 7 days prior to day 1 of therapy. Exception-Replacement steroid doses for adrenal insufficiency are permitted as necessary.
  • Subjects with active and uncontrolled autoimmune disease. Subjects with type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll.
  • Participants with new or progressive brain metastases (active brain metastases) or leptomeningeal disease must not require immediate CNS specific treatment at the time of study registration. Patients who have completed CNS therapy prior to starting therapy and clinically stabilized are also eligible.
  • Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or make study participation not in the best interest of the patient, in the opinion of the treating investigator.
  • Patient has known psychiatric or substance abuse disorders that, in the opinion of the investigator, would interfere with cooperation with the requirements of the trial.
  • Pregnant patients or patients planning donation of sperm or breast milk during the therapy and for a minimum of 5 months after stopping therapy.
  • Lactating patients if they do not agree to discontinue breast feeding through the entire duration of study participation and for 5 months after stopping therapy.
  • History of another metastatic/relapsed active malignancy. Localized skin cancers such as basal cell or squamous cell cancer are allowed.
  • Intractable nausea and vomiting refractory to therapy with antiemetics.
  • History of hypersensitivity to ipilimumab, nivolumab, inulin or the formulations excipients.
  • Known diagnosis of malabsorption disorder.
  • Concurrent use of probiotics or antibiotics.
  • Patients with a history of colectomy and/or gastric bypass.
  • Patients with a known diagnosis of active inflammatory bowel disease or irritable bowel syndrome.
  • History of organ transplant or stem cell/bone marrow transplant.
  • Patients with active Clostridium difficile infection within 3 months before therapy start. Active infection is defined as a stool sample positive for Clostridium difficile toxin by enzyme immunoassay (EIA) and either symptoms (frequent loose stools) OR imaging findings consistent with toxic megacolon.

Study Design

Enrollment

55 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Arm A (nivolumab, ipilimumab)

Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab monotherapy IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and blood sample collection throughout the study. Patients may optionally undergo biopsy during screening, on study, and at disease progression.

experimental: Safety run-in & Arm B (nivolumab, ipilimumab, inulin gel)

Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab monotherapy IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inulin gel PO BID for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients receiving benefit from study treatment may optionally continue receiving inulin gel PO BID beyond 52 weeks at the discretion of the treating physician and in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and blood sample collection throughout the study. Patients may optionally undergo biopsy during screening, on study, and at disease progression.

Interventions

Biopsy

Undergo biopsy

Biospecimen Collection

Undergo blood sample collection

Computed Tomography

Undergo CT

Inulin

Given PO

Ipilimumab

Given IV

Magnetic Resonance Imaging

Undergo MRI

Nivolumab

Given IV

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • 6-month progression free survival (PFS) [ Time Frame: At 6 months ]
  • Incidence of inulin gel related adverse events [ Time Frame: Up to 30 days after the last dose of inulin gel ]

Central Contacts and Locations

Central contacts

Cancer AnswerLine

1-800-865-1125CancerAnswerLine@med.umich.edu

Locations

University of Michigan Comprehensive Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Ulka N. Vaishampayan

734-936-7813vaishamu@med.umich.edu

Principal Investigator:

Ulka N. Vaishampayan

More Information

Sponsor

University of Michigan Rogel Cancer Center

Last update posted

Jul 31, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-25. This information was provided to ClinicalTrials.gov by University of Michigan Rogel Cancer Center on 2026-07-31. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.